| name | managing-pediatric-behavioral-health |
| description | Screens for and manages common pediatric behavioral and emotional conditions with school coordination. Use when screening pediatric mental health, coordinating with schools, or managing behavioral concerns. |
| tags | ["management","pediatrics"] |
| metadata | {"author":"casemark","practice_areas":["Pediatrics","Neonatology","Adolescent Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]} |
Managing Pediatric Behavioral Health
Screens for and manages common pediatric behavioral and emotional conditions including anxiety, depression, disruptive behavior disorders, trauma/adverse childhood experiences (ACEs), and autism spectrum disorder. Applies validated screening tools, coordinates school-based services, and integrates collaborative care models for mental health in the pediatric primary care setting.
Why This Skill Exists
Mental health conditions affect 1 in 5 children, but fewer than half receive treatment. Pediatric primary care is the de facto mental health system for most children — wait times for child psychiatry average 6-8 months in many regions. The AAP and AACAP have promoted collaborative care models and universal mental health screening in primary care. This skill ensures every well-child and concern-driven visit includes validated screening, risk stratification, evidence-based initial management, and appropriate referral pathways.
Checkpoint A — Intake Verification
Required Intake Questions
- What is the child's age (screening tools are age-specific)?
- What is the primary behavioral/emotional concern (as described by parent, teacher, and/or child)?
- When did symptoms begin and what was the temporal context (life event, school change, family stressor)?
- How are symptoms affecting function (school performance, peer relationships, family dynamics, daily activities)?
- Is there a family history of anxiety, depression, bipolar disorder, substance use, or suicide?
- Has the child experienced trauma, abuse, neglect, or significant adverse childhood experiences?
- Is the child currently receiving any behavioral health services (therapy, medication, school-based)?
- What is the sleep pattern (insomnia, nightmares, excessive sleep)?
- Are there any safety concerns (self-harm, suicidal ideation, aggression, homicidal ideation)?
Required Documents
- Completed screening questionnaires (PHQ-A, GAD-7, SCARED, PSC, ACE questionnaire)
- School records: report cards, behavioral reports, IEP/504 plan
- Prior behavioral health evaluations or therapy notes
- Medication history for psychotropic medications
- Family psychosocial history
Step 1 — Universal Screening (Bright Futures Schedule)
Recommended Screening Tools by Age and Condition
| Age | Screening Tool | Target Condition |
|---|
| All ages | Pediatric Symptom Checklist (PSC-17 or PSC-35) | General psychosocial function |
| 1-18 months | ASQ:SE-2 | Social-emotional development |
| 4-17 | ACEs questionnaire (PEARLS or similar) | Adverse childhood experiences |
| 8-17 | PHQ-2 → PHQ-A (if positive) | Depression |
| 8-17 | SCARED (Screen for Child Anxiety Related Disorders) | Anxiety |
| 12-18 | CRAFFT 2.1 | Substance use |
| 18-24 months | M-CHAT-R/F | Autism spectrum disorder |
| Any age with concern | Columbia Suicide Severity Rating Scale (C-SSRS) | Suicidal ideation/behavior |
Bright Futures Mental Health Screening Schedule
- Depression screening: universally at age 12+ per USPSTF; earlier if clinical concern
- Psychosocial screening: at every well-child visit (surveillance); formal screening per PSC at 4, 5, 6, 8, 10, 12, 14, 16, 18 years
- Substance use: annually starting at age 12 (CRAFFT)
- ACEs: at least once; ideally at initial visit and during high-risk periods
Step 2 — Anxiety Disorders
Common Presentations by Age
| Age | Common Anxiety Presentation |
|---|
| Preschool | Separation anxiety, selective mutism |
| School-age | Generalized anxiety, social anxiety, specific phobias |
| Adolescent | Social anxiety, generalized anxiety, panic disorder |
SCARED Screening
- 41 items, parent and child versions; scores ≥ 25 (child) suggest significant anxiety
- Subscales: panic/somatic, generalized anxiety, separation anxiety, social anxiety, school avoidance
- Administer both parent and child versions for concordance analysis
Management
- Mild-moderate: cognitive behavioral therapy (CBT) is first-line; evidence from CAMS study shows CBT alone effective in 60% of pediatric anxiety
- Moderate-severe or CBT-insufficient: SSRI medication
- Fluoxetine: 5-10 mg → titrate to 20-40 mg (FDA-approved for OCD in children ≥ 7)
- Sertraline: 12.5-25 mg → titrate to 50-200 mg (FDA-approved for OCD in children ≥ 6)
- Escitalopram: 5 mg → titrate to 10-20 mg (FDA-approved for depression ≥ 12)
- Combined CBT + SSRI: superior to either alone in moderate-severe anxiety (CAMS study)
- Monitor for activation syndrome in first 2-4 weeks of SSRI (agitation, insomnia, worsening anxiety — not the same as suicidality)
FDA Black Box Warning
- All antidepressants carry FDA black box warning for increased suicidal thinking/behavior in children and adolescents
- Monitor closely: weekly for first 4 weeks, biweekly for next 4, monthly thereafter
- Benefits of treatment generally outweigh risks for moderate-severe anxiety/depression
Step 3 — Depression
PHQ-A (Patient Health Questionnaire for Adolescents) Interpretation
| Score | Severity | Action |
|---|
| 0-4 | Minimal | Continued surveillance |
| 5-9 | Mild | Active monitoring; consider CBT |
| 10-14 | Moderate | CBT and/or SSRI; behavioral health referral |
| 15-19 | Moderately severe | SSRI + therapy; expedited referral |
| 20-27 | Severe | Urgent referral; safety assessment |
Always Ask Question 9
- PHQ-A item 9: "Thoughts that you would be better off dead or hurting yourself in some way"
- ANY positive response requires immediate safety assessment using C-SSRS
- Determine: passive ideation vs. active ideation; plan; means; intent; timeline
- If active ideation with plan: do not leave child unsupervised; initiate crisis intervention
Treatment
- Mild depression: active monitoring, psychoeducation, lifestyle interventions (exercise, sleep hygiene, social connection), supportive therapy
- Moderate-severe: fluoxetine (only SSRI with FDA approval for depression in children ≥ 8) + CBT or interpersonal therapy (IPT-A)
- Fluoxetine dosing: start 10 mg/day; may increase to 20 mg after 1-2 weeks if tolerated
- If fluoxetine fails or is not tolerated: escitalopram, sertraline, or citalopram as alternatives
- Avoid: paroxetine (negative studies in pediatrics), TCAs (cardiac risk), benzodiazepines for depression
Step 4 — Disruptive Behavior Disorders
Oppositional Defiant Disorder (ODD)
- Pattern of angry/irritable mood, argumentative/defiant behavior, vindictiveness lasting ≥ 6 months
- Differentiate from ADHD (impulsivity-driven defiance vs. deliberate opposition), anxiety (avoidance-driven refusal), and trauma (hyperarousal-driven aggression)
- Management: parent management training (PMT) is the evidence-based treatment
- Programs: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)
- No FDA-approved medication for ODD; treat comorbid conditions (ADHD, anxiety)
Conduct Disorder (CD)
- Persistent pattern of violating rights of others or age-appropriate societal norms
- Four categories: aggression to people/animals, destruction of property, deceitfulness/theft, serious rule violations
- Risk factors: family dysfunction, poverty, harsh parenting, peer deviance, callous-unemotional traits
- Management: multisystemic therapy (MST), functional family therapy, therapeutic foster care; psychiatric referral for severe cases
Step 5 — Adverse Childhood Experiences (ACEs) and Trauma
ACEs Screening
- Original ACE study (Felitti 1998): 10-item questionnaire covering abuse, neglect, household dysfunction
- PEARLS (Pediatric ACEs and Related Life-events Screener): expanded validated tool for clinical use
- ACE score ≥ 4: associated with dramatically increased risk of: depression, substance use, suicide attempts, chronic disease, early death
- Screening identifies toxic stress exposure; does not diagnose PTSD
Trauma-Informed Response
- Acknowledge the disclosure; express support without judgment
- Assess current safety (is the child currently in a safe environment?)
- Mandatory reporting if ongoing abuse or neglect is disclosed
- Refer for trauma-focused CBT (TF-CBT) — the most evidence-based therapy for pediatric PTSD
- Screening for trauma should NOT be a one-time event — revisit at subsequent visits
Building Resilience
- Stable, nurturing caregiver relationship is the strongest protective factor
- Encourage extracurricular activities, community connections, mentorship
- Address caregiver stress and mental health (two-generation approach)
Step 6 — School-Based Coordination
School-Based Services
- 504 plan: for mental health conditions that substantially limit a major life activity (learning, concentrating, socializing)
- IEP: if emotional disturbance qualifies under IDEA category "Emotional Disturbance" (ED)
- School-based counseling, social skills groups, behavioral intervention plans
Communication with Schools
- Obtain signed release of information from parent/guardian before communicating with school
- Provide written recommendations for accommodations (specific, actionable)
- Common accommodations: extended time, testing in separate room, reduced homework load, check-in with counselor, movement breaks, social skills groups
Crisis Planning
- Safety plan for children with suicidal ideation or self-harm: should exist at home AND school
- Safety plan components: warning signs, internal coping strategies, social contacts, adults who can help, professionals to contact, means restriction
Checkpoint B — Behavioral Health Review
Quality Audit
| Item | Requirement | Pass? |
|---|
| Screening completeness | Age-appropriate screening tool administered | |
| Safety assessment | Suicidal ideation directly assessed; C-SSRS if positive | |
| ACEs screening | Trauma history obtained | |
| Diagnostic rigor | DSM-5 criteria explicitly applied | |
| Treatment evidence | CBT/PMT/SSRI per guideline (not empiric benzodiazepines) | |
| SSRI monitoring | Black box counseling + monitoring schedule documented | |
| School coordination | Release signed; accommodations communicated | |
| Family involvement | Psychoeducation provided; caregiver mental health assessed | |
| Crisis plan | Safety plan created if suicidal ideation or self-harm | |
| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |
Guidelines
- Follow AAP 2018 Mental Health Competencies for Pediatric Practice
- Apply USPSTF recommendation for depression screening in adolescents (grade B, ages 12-18)
- Use PHQ-A (modified PHQ-9 for adolescents) as primary depression screen
- Use SCARED as primary anxiety screen (validated for ages 8-18)
- Follow AACAP Practice Parameters for: anxiety (2007), depression (2007), ODD/CD (2007), PTSD (2010)
- CAMS study: combined CBT + sertraline superior to either alone for moderate-severe pediatric anxiety
- TADS study: combined fluoxetine + CBT superior for adolescent depression; fluoxetine alone superior to CBT alone for depression
- Fluoxetine is the only SSRI with FDA approval for pediatric depression (ages ≥ 8)
- FDA black box: monitor all antidepressants closely for suicidal thinking in children/adolescents
- Collaborative care models (e.g., MCPAP, Project ECHO): leverage psychiatric consultation for primary care-based management
- Never prescribe benzodiazepines for pediatric anxiety or depression as first-line treatment
- This skill produces clinical documentation; it does not replace clinical judgment
